Opus Genetics Sets September Timeline for Key Gene Therapy Trial Data
Event summary
- Opus Genetics expects to announce three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 trial in early September 2026.
- The trial is evaluating the safety and efficacy of OPGx-BEST1 for BEST-1 associated inherited retinal diseases (IRDs).
- Cohort 1 includes five participants, with primary endpoints focused on safety and structural parameters like subretinal fluid reduction.
- A clinically meaningful reduction in subretinal fluid could justify advancing to Cohort 2 or even a pivotal trial.
The big picture
Opus Genetics' OPGx-BEST1 program is part of a broader push in gene therapy to address inherited retinal diseases, an area with significant unmet medical needs. The trial's adaptive design allows for rapid dose optimization, reflecting the industry trend toward flexible clinical development strategies. Success here could position Opus as a leader in BEST1-targeted therapies, potentially unlocking a market of over 20,000 patients globally.
What we're watching
- Clinical Efficacy
- Whether the 20% reduction in subretinal fluid will be achieved, indicating target engagement and supporting dose optimization.
- Regulatory Pathway
- How the FDA responds to the Month 3 data, which could influence the trial's next steps and potential acceleration.
- Market Reaction
- The investor response to the topline data, particularly given the high patient interest and unmet need in BEST1-associated IRDs.
Related topics